Corcept reported that relacorilant, its oral selective glucocorticoid receptor antagonist, reduced risk of death by 35% in a phase III ovarian cancer study, meeting overall‑survival and progression‑free endpoints. The result followed an earlier PFS readout and comes as the company prepares for a PDUFA date in mid‑2026 for platinum‑resistant ovarian cancer. Analysts and company commentary tied the trial outcome to commercial upside, with forecasts projecting multi‑hundred‑million to multi‑billion dollar peak sales depending on label scope and uptake. The data also follow a recent complete response letter in a different indication, illustrating regulatory complexity and the high stakes of phase III successes in oncology.